What happened in optometry this week: October 14 - October 18

Blog
Article

Catch up on what happened in optometry during the week of October 14-October 18.

Catch up with what Optometry Times shared this week:

FDA approves enVista Envy IOL from Bausch + Lomb

By Emily Kaiser Maharjan, Assistant Managing Editor

Bausch + Lomb announced FDA approval of its latest enVista intraocular lens (IOL), the Envy full range of vision IOL. The Envy offers a continuous range of vision that promotes dysphotopsia tolerance, according to the company.1 The lens demonstrated excellent long-term outcomes in US-based clinical trials as well as Canadian studies, and leverages ActivSync Optic intelligent energy distribution to perform well in all lighting conditions.2,3 The enVista Envy was previously approved by Health Canada in May of 2024.

Read more...

Rising diabetic retinopathy rates in youth could indicate potential public health crisis

By David Hutton, Managing Editor, Ophthalmology Times

Diabetic retinopathy has tended to be regarded as a rare occurrence in young patients diagnosed with diabetes, but a recent paper details the growing rates of the disease in young people as a looming “potentially unappreciated public health catastrophe.”

Read here...

You and Eye: Myopia cannot be viewed as a specialty in today's practice setting

By Miriam Korik, OD; Justin Kwan, OD, FAAO; and Emily Kaiser Maharjan, Assistant Managing Editor

In this episode of the You and Eye podcast, Miriam Korik, OD, and Justin Kwan, OD, FAAO, delve into the evolving landscape of myopia management within optometry, reflecting on its transition from a niche specialty to a crucial component of primary care. Drawing on their experiences and insights, they discuss the growing prevalence of myopia and the pressing need for more optometrists to integrate effective management strategies into their practices. Kwan shares practical advice for new graduates and seasoned practitioners alike, emphasizing the importance of collaboration and support when introducing myopia management techniques. They explore various methods for starting this process, even in practices without advanced technology, while also highlighting the value of utilizing available resources and consultants. This dialogue underscores the significance of proactive eye care in addressing the myopia epidemic and equips optometrists with actionable steps to enhance their practice.

Listen here...

That’s some nerve! Ocular drug delivery and dry eye

By Katherine M. Mastrota, MS, OD, FAAO, Dipl ABO

Eye care’s earliest stabs at treating ocular surface disease (OSD; also referred to as dysfunctional tear film, dry eye disease [DED] or syndrome, lacrimal keratoconjunctivitis, keratitis sicca, meibomian gland [MG] dysfunction, etc) primarily aimed to add eye elements that were lacking in the tear film to the surface of the eye or to reduce tear film instability. The tear film was supplemented via solutions, gels, suspensions, ointments, emulsions, and/or dissolving conjunctival cul-de-sac inserts. As we became sophisticated in our experience and knowledge of the eye surface and tear production, we learned that tempering inflammation was paramount to managing disease signs and symptoms. The molecules that modulate inflammation are also added to a variety of vehicles that are dripped onto the eye surface. Autologous serum and, more recently, recombinant human nerve growth factors are also instilled topically in the eye. Additionally, more than a dozen dry eye pipeline drugs are stated to be delivered via local, topical application.

Read here...

Ocular Therapeutix accelerates timelines for SOL-1 Phase 3 trial of Axpaxli for wet AMD

By Jordana Joy, Associate Editor

Biopharmaceutical company Ocular Therapeutix has announced accelerated timelines for its SOL-1 Phase 3 registrational clinical trial of Axpaxli for wet age-related macular degeneration (AMD).1 The study is now expected to be fully enrolled with all 300 patients randomized by the end of 2024, with topline data now expected during the fourth quarter of 2025, according to a news release. Prior guidance for Ocular Therapeutix was to complete enrollment by the end of the first quarter of 2025.1

Read here...

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Eva Kim, MD, shares visual outcomes of EVO implantable collamer lens in patients with low to moderate myopia
Drs Brianna Rhue and Diana Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.
Dr Ashley Wallace Tucker speaks on the Myopia Management Navigator.
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Arkansas Optometric Association legislative cochairs Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD, discuss their involvement in their bill and provide context for its relevance.
Elise Kramer, OD, FAAO, FSLS, describes her take on a multidisciplinary approach to dry eye
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
© 2025 MJH Life Sciences

All rights reserved.